Cerebiome

PreclinicalSmall molecule

SSt Joseph University, Beirut, Lebanon

Cerebiome is one of 39 small molecule programs targeting Mood Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mood DisorderActive, not recruiting

Mood DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Mood Disorder

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

1 2

Depakote

AbbVie

Approved

1 3

Tegretol

Novartis

Approved

1 4

Bayer Aspirin

Bayer

Approved

1 5

Brintellix

Geodon

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

3 8

Lamictal

GGlaxo Dba Glaxosmithkline

Approved

3 9

Zoloft

VViatris Specialty LLC

Approved

3 10

Effexor

WWyeth-Lederle Vaccines

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mood Disorder1 trial

Gut Microbiota in Mood Disorders in Lebanese Population

Completed·SSt Joseph University, Beirut, Lebanon·N/A·NCT05646784·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cerebiome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cerebiome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cerebiome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St Joseph University, Beirut, Lebanon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSt Joseph University, Beirut, Lebanon

Cerebiome

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mood Disorder1 trial

References

Drug Info

Quick Facts

Related News